文献速递腹部介入CTMRUS

不可切除结直肠癌肝转移患者不同热消融策略的结局

Outcomes Following Different Thermal Ablation Strategies in Patients with Unresectable Colorectal Liver Metastases.
PubMed 文献 · Radiology · 2023-01-01

这项回顾性研究纳入七家医院255例延迟消融和103例 upfront 消融的不可切除结直肠癌肝转移患者(病灶≤3个且直径<3 cm),倾向性评分匹配后各100例。upfront 消融组5年无病生存率优于延迟消融组(36% vs 21%;P = .02),5年总生存率无显著差异(延迟消融59% vs upfront 消融64%;P = .49),消融并发症和药物相关不良事件率无差异。

要点

  • 不可切除CRLM病灶≤3个且<3 cm时,upfront消融较延迟消融5年DFS更优(36% vs 21%;P = .02)。
  • 两策略5年OS无显著差异(延迟消融59% vs upfront消融64%;P = .49)。
  • 消融并发症率(延迟消融6% vs upfront消融5%;P = .76)和药物不良事件率(均为9%;P = .99)无差异。

核心结论

  • 在病灶较少(≤3个)且较小(<3 cm)的不可切除CRLM患者中,upfront热消融联合辅助全身治疗较延迟消融获得更好的DFS。

研究设计与样本

  • 回顾性研究纳入七家医院2009年10月至2020年12月收治的不可切除CRLM患者(病灶≤3个;直径<3 cm),延迟消融255例(平均年龄57岁±11;男184例[72%]),upfront消融103例(平均年龄56岁±12;男72例[70%]);upfront消融在全身治疗开始前2-4周进行,延迟消融在全身治疗开始后2-3个月进行;采用倾向性评分匹配(每组100例)调整基线变量;主要结局为无病生存期(DFS),次要结局为总生存期(OS)、并发症和不良事件;采用log-rank检验比较组间结局。

诊断标准与关键数值

  • 倾向性评分匹配后(每组100例),upfront消融组5年DFS为36%,延迟消融组为21%(P = .02)。
  • 5年OS延迟消融组为59%,upfront消融组为64%(P = .49)。
  • 消融并发症率延迟消融组为6%,upfront消融组为5%(P = .76)。
  • 药物相关不良事件率延迟消融组和upfront消融组均为9%(P = .99)。

临床应用与阅片要点

  • 对于病灶≤3个且直径<3 cm的不可切除CRLM,upfront热消融联合辅助全身治疗较延迟消融可能带来更好的DFS。
  • 两种消融策略在OS、消融并发症和药物相关不良事件方面无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background For patients with unresectable colorectal liver metastases (CRLM), clinical guidelines recommend imaging-guided thermal ablation combined with systemic therapy. However, the optimal thermal ablation strategy remains unclear. Purpose To compare long-term outcomes between patients who underwent upfront ablation or delayed ablation for unresectable CRLM. Materials and Methods This retrospective study included patients with unresectable CRLM (three or fewer lesions; diameter, <3 cm) admitted to one of seven hospitals between October 2009 and December 2020. Upfront ablation was performed 2-4 weeks before the start of systemic therapy, and delayed ablation was performed 2-3 months after the start of systemic therapy. Propensity score matching was applied to adjust for differences in baseline variables between groups. Disease-free survival (DFS) was the primary outcome. Overall survival (OS), complications, and adverse events were secondary outcomes. Outcomes were compared between groups by using the log-rank test. Results In total, 255 patients who underwent delayed ablation (mean age, 57 years ± 11 [SD]; 184 men [72%]) and 103 patients who underwent upfront ablation (mean age, 56 years ± 12; 72 men [70%]) were included. After propensity score matching (n = 100 in both groups), the 5-year DFS for patients who underwent upfront ablation was better compared with patients who underwent delayed ablation (36% vs 21%; P = .02). For 5-year OS, no evidence of a difference was observed between ablation strategies (delayed ablation, 59% vs upfront ablation, 64%; P = .49). Additionally, no differences were observed between ablation strategies with respect to the rates of ablative complications (delayed ablation, 6% vs upfront ablation, 5%; P = .76) or drug-related adverse events (delayed and upfront ablation both 9%; P = .99). Conclusion In patients with relatively few (three or fewer) and small (<3 cm) unresectable CRLM, upfront thermal ablation combined with adjuvant systemic therapy led to better DFS compared with delayed ablation. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Georgiades in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Li J, Liu G, Xie X, et al. Outcomes Following Different Thermal Ablation Strategies in Patients with Unresectable Colorectal Liver Metastases. Radiology. 2023. PMID: 37581502. doi:10.1148/radiol.223135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。